CentraleSupélec Venture
VC Fund
Paris, France
CentraleSupélec Venture is a VC fund in Paris focused on Medical and Biotechnology. CentraleSupélec Venture est un fonds de capital-risque early-stage, créé par l’Ecole CentraleSupélec.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries CentraleSupélec Venture invests in
Stages CentraleSupélec Venture invests in
Countries CentraleSupélec Venture invests in
Round sizes
Round size
- Seed
- $412k–$5.8M
Investment Focus
Industry
- Medical 3 (33%)
- Biotechnology 2 (22%)
- Artificial Intelligence 2 (22%)
- B2B 1 (11%)
- SaaS 1 (11%)
Stage
- Seed 8 (89%)
- Pre-Seed 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ed AI provides an AI platform for automated grading, feedback, and personalized learning materials in education. | $5.8M / Seed / Sep 11, 2026 | ||
| En Carta Diagnostics develops molecular diagnostic technologies that enable the rapid detection of DNA and RNA pathogens at the point of care. The company designs programmable diagnostic platforms that deliver laboratory-grade molecular testing without requiring specialized equipment or extensive technical training. Its technology uses syntheticbiology and portable diagnostic devices to support the detection of infectious diseases, including Lyme disease, as well as other bacterial and viral pathogens. En Carta Diagnostics also develops custom molecular diagnostic solutions and expands its platform to address a broad range of genetic and infectious disease applications. The company collaborates with research institutions and applies its proprietary diagnostic technology to improve the accessibility and reliability of molecular testing across healthcare settings. | $3.4M / Seed / Jul 10, 2026 | ||
| Rewake is a refurbishing company that offers laboratories with reconditioned equipment and instruments at half the price of new to make them usable again. | $412.2K / Seed / Jan 14, 2025 | ||
| Trace For Good is a traceability and social and environmental data management platform that allows retail businesses to engage with their suppliers using a single source of information. | $3.7M / Seed / Nov 12, 2024 | ||
| Dans un contexte de transition énergétique et d’augmentation structurelle des prix, bien suivre et prévoir vos consommations en énergie devient un enjeu majeur. Chez Highcast, nous voulons relever ce défi autour de 3 axes : - Maîtriser et expliquer votre budget - Contribuer à la transition énergétique - Optimiser vos approvisionnements | $2.2M / Seed / Oct 09, 2024 | ||
| En Carta Diagnostics develops molecular diagnostic technologies that enable the rapid detection of DNA and RNA pathogens at the point of care. The company designs programmable diagnostic platforms that deliver laboratory-grade molecular testing without requiring specialized equipment or extensive technical training. Its technology uses syntheticbiology and portable diagnostic devices to support the detection of infectious diseases, including Lyme disease, as well as other bacterial and viral pathogens. En Carta Diagnostics also develops custom molecular diagnostic solutions and expands its platform to address a broad range of genetic and infectious disease applications. The company collaborates with research institutions and applies its proprietary diagnostic technology to improve the accessibility and reliability of molecular testing across healthcare settings. | $1.6M / Pre-Seed / May 22, 2024 | ||
| Scienta Lab is an AI-powered platform pioneering Precision Immunology | $4.3M / Seed / Dec 05, 2023 | ||
| In the biotech space, cell and gene therapy and clean meat are two of the most promising industries. Yet both are facing the same issue: large-scale cell culture remains the blocking point to scale up and make both cell and gene therapies and clean meat accessible and affordable. To that end, Kolibri is building a proprietary cell-engineeringplatform, combining cutting edge techniques in acoustics and biology, allowing for a 90x higher yield while decreasing production costs up to 50x. | $2.8M / Seed / Mar 06, 2023 | ||
| Exwayz is a software development platform that specializes in real-time 3D LiDAR processing solutions. | $1.2M / Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CentraleSupélec Venture invest in?
CentraleSupélec Venture invests primarily in Medical, Biotechnology and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does CentraleSupélec Venture invest in?
CentraleSupélec Venture typically joins rounds of $412k–$5.8M at Seed. These are whole funding-round sizes, not CentraleSupélec Venture's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds CentraleSupélec Venture took part in.
When did CentraleSupélec Venture last invest?
The most recent investment recorded for CentraleSupélec Venture closed in Sep 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
